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Background: The NHS Bowel Cancer Screening Programme (BCSP) in England does not involve general practitioners (GPs).
Uptake is B58%. The Practice Endorsed Additional Reminder Letter (PEARL) study piloted a GP-endorsed reminder letter.
Methods: General practices in Wessex with uptake o55% (prevalent invitations) were invited to participate. Subjects who had
been invited for screening, sent a standard 28-day BCSP reminder letter but had not returned a test kit within 30 days of the
standard reminder were sent a second reminder letter bearing the GP’s letterhead and signature. Uptake was compared between
PEARL and non-PEARL practices by standardised uptake ratio (standardised for prior prevalent uptake and other confounders). In
addition, 25 non-PEARL practices were matched with PEARL practices for prior prevalent uptake and number of invitees.
Results: Twenty-five practices agreed to participate. A total of 3149 GP-endorsed reminders were sent. Uptake in the PEARL
practices was 54% compared with 51% in the matched-control practices. The adjusted RR for uptake was 1.08 (95% CI: 1.05, 1.11,
Po0.001) for all invitees and 2.18 (1.79, 2.66, Po0.001) for invitees who had not returned a kit following the standard reminder.
Conclusions: The GP-endorsed reminder was associated with significantly increased uptake among subjects not responding to
the standard reminder letter.
Worldwide, colorectal cancer (CRC) is a major health burden; in
2012, nearly 1.4 million cases were diagnosed and there were
694 000 deaths (Ferlay et al, 2013). Screening using guaiac-based
faecal occult blood testing (gFOBt) reduces mortality from CRC, as
demonstrated by several population-based randomised controlled
trials (Mandel et al, 1993; Kewenter et al, 1994; Hardcastle et al,
1996; Kronborg et al, 1996). The Bowel Cancer Screening
Programme (BCSP) was implemented by the National Health
Service (NHS) in England in 2006 and is delivered by five regional
Hubs. Men and women aged 60–74 years (inclusive) receive an
invitation to participate in screening using gFOBt every 2 years.
The initial stage of the process is a pre-invitation letter that
explains the disease and how the screening programme works.
A week later, a gFOBt kit is sent out with another invitation letter.
All correspondence from the Hub is signed by the BCSP Hub
Director, who is most likely unknown to the subject receiving the
letter due to the large geographical regions covered by each Hub.
The gFOBt requires participants to smear two small faecal
samples from each of three separate stools onto a card that, when
complete, is returned in the post to the BCSP Hub for analysis.
Participants that receive a positive (abnormal) test result are
referred for a follow-up investigation; if the test is negative
(normal), participants will be invited to be screened again in 2
years’ time until they reach the age of 75 (after which
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time individuals may self-refer). A reminder letter is sent to
subjects where no action has occurred on the Bowel Cancer
Screening System within 28 days of being sent a test kit. Screening
episodes are closed if there is no response 17 weeks after the kit was
sent.
In England, ‘uptake’ of screening is defined as the proportion of
invited subjects that is adequately screened (definitive positive or
definitive negative test result) within 26 weeks of invitation. Overall
uptake in England was 58.2% in 2014/2015 (personal commu-
nication, National Office), considerably lower than in the breast
and cervical screening programmes (Douglas et al, 2016. There is
wide variation in uptake across the country. BCSP data have
demonstrated uptake to be as low as 35% in the most deprived
areas and as high as 63% in least deprived areas (von Wagner et al,
2011).
There is evidence to suggest that people are more likely to
respond to an invitation to screening if they are encouraged to do
so by their GP or another health professional (Cole et al, 2002;
Senore et al, 2010; Zajac et al, 2010; Hewitson et al, 2011;
Camilloni et al, 2013; Shankleman et al, 2014; Massat et al, 2014;
Hall et al, 2015; Wardle et al, 2015).
The aim of the Practice Endorsed Additional Reminder Letter
(PEARL) project was to develop and pilot a sustainable interven-
tion to engage subjects in bowel cancer screening. The project was
designed to test whether an additional reminder letter on GP-
headed paper and with the signature of the subject’s GP could
encourage uptake. It is the result of collaboration between the
BCSP Southern Hub, a group of GPs in Wessex (Hampshire,
Dorset and the Isle of Wight) working for Macmillan Cancer
Support and Cancer Research UK, in partnership with the Wessex
Strategic Clinical Network.
MATERIALS AND METHODS
Target population. The BCSP Southern Hub serves the south of
England (excluding London), sending 20 000 invitations for
screening every week. The PEARL project tested the intervention
in the target area of Wessex. All general practices in Wessex with
an uptake of less than 55% (‘prevalent’ episodes only and
calculated for all screening data up to 10 September 2013) were
invited to participate. These practices were typically in areas of
socioeconomic deprivation. The PEARL intervention targeted all
subjects aged 60–74 years (inclusive), registered with a participat-
ing practice who were invited to take part in screening and had not
responded to the standard 28-day BCSP reminder letter.
Recruitment and participants. Eligible practices were contacted
by e-mail and regular mail to invite them to participate. If no reply
was received, they were contacted by telephone. The deadline for
agreement to participate was 31 May 2014. Participating practices
agreed to receive an educational 1-h visit to learn about the BCSP,
the PEARL project and to discuss the practice-specific statistical
cancer profile—the National Cancer Intelligence Network general
practice profile. Practices were offered a financial incentive (d250)
for participating in the project.
Each practice signed a consent form and a confidentiality agreement
and data exchange form, which set out the responsibilities of both the
Hub and the GP practice (Supplementary web-Appendix A).
The text of a standard second reminder letter (Supplementary
web-Appendix B) was approved by the BCSP National Office.
Each participating practice sent the Hub a paper or scanned
electronic copy of the practice letterhead and a digital GP
signature. One GP signed the letter for all patients from the
practice. An electronic letter template was constructed for each
practice.
Method. The PEARL intervention took place in Wessex between
September 2014 and October 2015 and was designed to run for a
fixed period of time. The flowchart in Figure 1 summarises the
PEARL process. On the first Wednesday of each month, BCSP
subject-level data (subject name, address, number of test kits sent,
number of test kits returned, date of initial invitation, date
standard 28-day reminder letter sent) for each participating
practice were downloaded from the ORACLE-based BCSP
database (Bowel Cancer Screening System). The full name, NHS
number, and address of all non-responders whose kit had been
sent out 60–90 days prior to the extract date were entered onto a
spreadsheet for each practice and sent using secure mail. The broad
60–90-day range is due to the programme download being run on
a single day each month, and using a 30-day moving window to
ensure no subjects were missed. The practice reviewed each
subject’s history and indicated on the spreadsheet using a drop-
down menu whether the subject should be sent an additional
reminder.
GPs returned completed spreadsheets to the Hub by secure
e-mail.
Ten working days after the initial list was sent, the list of
subjects on returned GP spreadsheets was checked against a new
download of subject-level data from Bowel Cancer Screening
System to ensure that subjects remained non-respondent, were still
registered with the same GP, and that there was no record of death.
GP-endorsed reminder letters were printed for all eligible subjects
with the appropriate GP letterhead and signature. This process was
repeated 15 working days after the initial list for any GP
spreadsheets returned late.
In any 1 month, if no non-responders were identified for a
participating practice, the practice was notified by e-mail that they
would not receive a list that month. Practices that did not return a
completed spreadsheet were sent a reminder e-mail 5 working days
after the spreadsheet was sent.
The average date of sending a GP-endorsed reminder was 99
days after initial invitation. Subjects in PEARL-registered practices
not sent a reminder and in the non-PEARL practices were assigned
an index date, the date when a PEARL reminder would have been
sent if the practices were participating and the subject had not yet
returned an adequate kit. Uptake, the primary outcome measure,
was defined as the proportion of subjects (of the overall invited
population and of those not adequately screened before the index
date) that was adequately screened. Uptake was compared between
PEARL practices and all other practices in the Southern Hub
region with a prevalent uptake of less than 55%. The comparison
group included all routine screened Southern Hub subjects with an
invitation on days that PEARL subjects were invited.
Subject variables were sex, age-group, and screening history
(categorised as ‘prevalent’ first-time invitee or previous non-
responder or ‘incident’ previous responder, plus sequence of
episode—first, second, third, etc). In addition, a measure of social
deprivation (index of multiple deprivation (IMD)) was assigned for
each subject with reference to the English indices of deprivation.
The IMD scores were grouped into quintiles based on national
distributions with the use of predefined national cutoffs.
Statistical methods. Both the 25 PEARL-registered practices and
the 1575 comparison practices were specified to have prevalent
screen participation rates of less than 55% prior to the intervention.
However, even within this range, the comparison practices had
substantially higher prior participation rates than the PEARL-
registered practices (see Results section). We therefore analysed the
data analogously to standardised incidence or mortality ratios.
Using logistic regression, in subjects within the comparison
practices only, we estimated the effects of age, sex, prior prevalent
participation, IMD quintile, episode type (prevalent or incident),
and episode sequence on the probability of participation. These
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were applied to the subjects in the PEARL-registered practices to
calculate the expected proportion of participants in these practices
(see Supplementary web-Appendix C for mathematical details).
The effect of the intervention was estimated as the observed
number of participants in the PEARL-registered practices divided
by the expected number. We calculated confidence intervals on the
ratio assuming a binomial distribution of numbers participating,
taking into account the uncertainty in the expected numbers.
For subjects in the non-PEARL-registered practices, the index
date was defined as the date on which a PEARL reminder would
have been due if these had been PEARL subjects. Our primary
analysis was to compare the participation rate of subjects in the
PEARL-registered practices with that expected from the compar-
ison practices, for overall participation and for participation in
those not returning an adequate kit by the index date, unstratified
by demographic or screening data. Secondary analysis consisted of
the same comparisons in subgroups of age, sex, screening episode
type (prevalent or incident), and IMD quintile.
As a check on our method, we also selected 25 non-PEARL
practices, matched to the PEARL-registered practices by previous
prevalent participation rates and number of invitees. We repeated
our primary analysis, directly comparing participation rates in
PEARL-registered practices with those in the matched non-PEARL
practices. Analysis for this comparison was performed using
inverse variance weighted average estimation conditioning on
matched set (Cummings, 2009). All analyses were performed in
Stata version 13.1 (StataCorp, 2013).
Funding and ethics. The PEARL project protocol was approved
by the NHS BCSP Research Committee in March 2015 (reference
ID 148). The Office for Data Release granted permission for
sharing BCSP data with Professor Stephen Duffy (statistician) in
November 2015 (reference ODR1516_154). Patient consent was
not required under Section 251 of the 2006 NHS Act. The PEARL
project is part of the ACE (Accelerate, Coordinate, Evaluate)
programme, NHS England’s initiative supported by Cancer
Research UK and Macmillan Cancer Support to diagnose cancer
early and improve outcomes. Funding was received from the
National Cancer Intelligence Network.
RESULTS
Of the 43 eligible practices approached, 25 agreed to participate in
the PEARL study. Over the 14-month study period, 324 non-
participating subject lists were sent to GP practices. Seventeen
practices had lists to review every month. For 11 of the study
months, there were practices (n¼ 1–7) that received no list. The
mean number of subjects on each list was 16.02 (range 1–103).One
hundred twenty-four (38.3%) lists were not returned. Two of the
practices that signed up to the PEARL intervention did not return
any of the lists.
One hundred sixty-one (5.11%) subjects were deemed unsui-
table by the GP to receive a reminder letter for the following
reason:
 Patients receiving end-of-life care (n¼ 10)
 Already having regular colonoscopy surveillance (n¼ 20)
 Recent (o12 months) diagnosis of bowel cancer (n¼ 4)
 Unable to have colonoscopy (n¼ 5)
 Other (n¼ 122).
There were 12 878 invitees in the PEARL-registered practices
and 1 248 689 in the non-PEARL-registered practices. A total of
3149 GP-endorsed reminder letters were sent.
Table 1 shows the characteristics of subjects in the PEARL-
registered practices, in those practices matched to the PEARL
Day 1 of the month
(a) Subject data for participating practices
downloaded from BCSS1 and non-
responders2 flagged.
(b) Non-responder details entered onto a
spread sheet and sent to participating
practices using secure email.
(c) GP reviews the spread sheet, indicates subjects
who should not receive an additional GP-endorsed
reminder letter and returns the list to the Hub
using secure email.
Day 10 of the month
(d) Returned spread sheets reviewed, subject details
cross checked for updates to non-responder status and
subjects eligible for GP-endorsed reminder letter flagged.
(e) For eligible non-responders, GP-endorsed reminder letters
printed on GP-headed paper with GP signature and despatched.
Day 15 of the month
(f) Repeat (d)–(e) for spread sheets returned late.
Figure 1. Schematic representation of PEARL process. 1BCSS: Bowel Cancer Screening System; 2Non-responders defined as subjects who had
not returned a test kit within 30–60 days of a standard reminder letter.
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practices, and in all the comparison practices. There were
substantial differences between the invitees in the PEARL-
registered practices and those in the non-PEARL-registered
practices. In particular, the former were much more likely to be
in deprived IMD categories. This is reflected in the fact that
average prior prevalent participation in the PEARL-registered
practices was 36%, substantially lower than that observed in the
non-PEARL practices, 47%. This necessitated the approach
described above, deriving results standardised for age, sex, IMD
quintile, episode type, episode sequence, and prior prevalent
participation. The differences between the PEARL practices and
the matched practices are much attenuated, and the average prior
prevalent participation in the matched practices was 36%, as in the
PEARL-registered practices. Table 2 shows the numbers returning
a completed kit by the index date in the same groups.
Table 3 shows the basic results with respect to participation.
There was a highly significant (Po0.001) difference between the
participation rates in the PEARL practices and that expected from
the non-PEARL, with 6914 (54%) participation vs 6543 (51%)
expected. In those who qualified for a reminder, that is, those who
had not returned a completed kit by the index date, there was also
a highly significant difference (Po0.001) with 362 (7%) participa-
tion in the PEARL practices compared with 167 (3%) expected.
The direct comparison of the 25 PEARL practices with the 25
matched practices showed slightly stronger but essentially similar
results (Table 4).
Table 5 shows the subgroup results by age, sex, screen type
(prevalent/incident), and socioeconomic status as measured by
IMD quintile, for all invitees, and for those not returning a
completed kit by the index date. In the upper half of the table, all
invitees, it can be seen that significantly greater participation than
expected was noted in the PEARL practices for all subgroups
except for subjects aged 65 years or less, with absolute differences
ranging from 2 to 5%. The difference in the effect of the PEARL
intervention between age groups was statistically significant
(P¼ 0.001). No other significant heterogeneity of the PEARL
intervention effect between subgroups was observed.
In the corresponding results in the lower half of the table, for
those with no return of an adequate kit before the index date, all
subgroups showed highly significant results, with an approximate
doubling of the rate of participation, typically from 2–3 to 6–8%.
Again, there was significant heterogeneity of the effect by age, with
a stronger effect of the PEARL intervention in those older than 65
years. No other significant heterogeneity of the intervention effect
was observed between subgroups.
Using the method and rates given by Raine et al (2016), we
predict the effect of increased uptake of screening from PEARL on
observed outcomes nationally. In the 2014/2015 fiscal year,
4 117 866 people were invited for screening by the BCSP in
England. An increase of 3% suggests that if PEARL was
implemented nationally then an extra 123 536 each year would
be screened. In 2014/2015, the positivity rate among the screened
population was 1.79%, and 87.39% of these attend a specialist
screening practitioner clinic. In all, 8.09% will have a colorectal
cancer and 23.43% will have medium- or high-risk polyps. Hence,
if PEARL were implemented nationally, this could detect up
Table 1. Characteristics of invitees in PEARL and comparison practices
Factor Category
No. (%) in PEARL
practices
No. (%) in practices matched
to PEARL practices
No. (%) in all non-PEARL
practices
Age p65 6096 (47) 6210 (52) 576 764 (46)
66þ 6782 (53) 5648 (48) 671 925 (54)
Sex Male 6642 (52) 5934 (50) 607 256 (49)
Female 6236 (48) 5924 (50) 641 433 (51)
Screen type Prevalent 6373 (49) 6295 (53) 524 744 (42)
Incident 6505 (51) 5563 (47) 723 945 (58)
IMD quintile
1 (most deprived) 3759 (29) 2724 (23) 73 797 (6)
2 3033 (24) 3267 (28) 182 497 (15)
3 2836 (22) 2251 (19) 291 373 (24)
4 2190 (17) 1218 (10) 310 743 (25)
5 (least deprived) 996 (8) 2332 (20) 380 078 (31)
NK 64 66 10 201
All N/A 12 878 11 858 1 248 689
Abbreviations: IMD¼ index of multiple deprivation; N/A¼not applicable; NK = not known; PEARL = Practice Endorsed Additional Reminder Letter.
Table 2. Numbers (%) adequately screened on or before the index date
Factor Category PEARL practices Practices matched to PEARL practices All non-PEARL practices
Age p65 2741 (45) 2661 (43) 308 777 (54)
66þ 3662 (54) 2891 (51) 415 329 (62)
Sex Male 3070 (46) 2606 (44) 332 011 (55)
Female 3333 (53) 2946 (50) 392 095 (61)
Screen type Prevalent 1279 (20) 1189 (19) 129 433 (25)
Incident 5124 (79) 4363 (78) 594 673 (82)
IMD quintile
1 (most deprived) 1539 (41) 1029 (38) 32 010 (43)
2 1391 (46) 1436 (44) 92 912 (51)
3 1515 (53) 1035 (46) 165 219 (57)
4 1310 (60) 662 (54) 187 682 (60)
5 (least deprived) 610 (61) 1358 (58) 240 334 (63)
NK 38 (59) 32 (48) 5949 (60)
All N/A 6403 (50) 5552 (47) 724 106 (58)
Abbreviations: IMD¼ index of multiple deprivation; N/A¼not applicable; NK = not known; PEARL = Practice Endorsed Additional Reminder Letter.
BRITISH JOURNAL OF CANCER The PEARL project
1554 www.bjcancer.com | DOI:10.1038/bjc.2017.129
to an additional 453 people (123536*0.0179*0.8739*0.2343)
with high- or intermediate-risk polyps, and 156 people
(123536*0.0179*0.8739*0.0809) with a colorectal cancer each year.
DISCUSSION
Our results indicate that the addition of a GP-endorsed reminder
at 3 months significantly increased participation in the NHS BCSP,
by 3% in absolute terms (54% vs 51%), in general practices with
participation rates below the national average. There is already
evidence that primary care endorsement improves participation in
screening for a number of cancers (Duffy et al, 2016) and this study
provides further evidence to support this.
Our aim was to develop a robust, feasible, and sustainable
method to increase uptake through direct GP endorsement of the
BCSP in England. Although previous studies have demonstrated
that GP endorsement is successful in increasing uptake in the
programme (Cole et al, 2002; Senore et al, 2010; Zajac et al, 2010;
Hewitson et al, 2011; Camilloni et al, 2013), these studies have not
considered the long-term feasibility of uptake initiatives directly
involving GP practices and, to our knowledge, none has targeted
non-responders and asked GPs to assess the appropriateness of
sending a subject a reminder letter.
Hall et al (2015) conducted a qualitative study using in-depth
interviews with BCSP non-participants and found that non-
participation in screening was not necessarily associated with
negative attitudes towards screening or a decision not to return
a kit. The authors concluded that some non-participants may
have a degree of intention to take part in screening in the
future and may be more responsive to interventions based on
professional endorsement and reminders. The results from our
study support this.
Another RCT was conducted in the south of England in 2009
among 20 general practices (1288 subjects invited for screening)
(Hewitson et al, 2011). Subjects were randomised to either a GP-
endorsed letter and/or an enhanced information leaflet with their
gFOBT kit. The GP-endorsed letter and the enhanced procedural
leaflet increased uptake by 5.8% and 6.0%, respectively, and had an
additive effect (11.8%).
Table 3. Effect of intervention on participation in PEARL practices
Population
Observed/expected participating
subjects in PEARL practices No. (%) participating O/E (95% CI) Significance
All invitees
Observed 6914 (54)
1.06 (1.03–1.09) Po0.001Expected 6543 (51)
Those not returning on Observed 362 (7) 2.17 (1.96–2.40) Po0.001
or before index date Expected 167 (3)
Abbreviations: CI¼ confidence interval; O/E = Observed/Expected; PEARL = Practice Endorsed Additional Reminder Letter.
Table 4. Effect of intervention on participation from the direct comparison with matched practices
Population Study group No. (%) participating RR (95% CI) Significance
All invitees Comparison practices 5861/11 858 (49) 1.00 ( ) Po0.001
PEARL practices 6914/12 878 (54) 1.08 (1.05–1.11)
Those not returning on or before index date Comparison practices 144/5417 (3) 1.00 ( ) Po0.001
PEARL practices 362/5535 (7) 2.18 (1.79–2.66)
Abbreviations: CI¼ confidence interval; PEARL = Practice Endorsed Additional Reminder Letter; RR = relative risk.
Table 5. Effect of intervention on participation in subgroups of PEARL practices by age, sex, screen type, and IMD quintile
Observed and expected numbers










Age p65 years 2987 (49) 2966 (49) 6096 1.01 (0.97–1.05) P¼ 0.6
Age 465 years 3927 (58) 3577 (53) 6782 1.10 (1.06–1.14) Po0.001
Males 3347 (50) 3184 (48) 6642 1.05 (1.01–1.09) P¼ 0.005
Females 3567 (57) 3359 (54) 6236 1.06 (1.02–1.10) Po0.001
Prevalent screen 1465 (23) 1345 (21) 6373 1.09 (1.03–1.15) P¼ 0.001
Incident screen 5449 (84) 5197 (80) 6505 1.05 (1.02–1.08) Po0.001
Most deprived quintile 1657 (44) 1578 (42) 3759 1.05 (1.00–1.11) P¼ 0.05
Other four quintiles 5218 (58) 4933 (54) 9055 1.06 (1.03–1.09) Po0.001
Subjects not returning an
Age p65 years 181 (6) 104 (4) 2949 1.74 (1.49–2.03) Po0.001
adequate kit by the index date
Age 465 years 181 (7) 63 (2) 2586 2.87 (2.42–3.41) Po0.001
Males 195 (6) 95 (3) 3058 2.05 (1.78–2.36) Po0.001
Females 167 (7) 73 (3) 2477 2.29 (1.96–2.67) Po0.001
Prevalent screen 157 (4) 70 (2) 4484 2.24 (1.90–2.63) Po0.001
Incident screen 205 (20) 97 (9) 1051 2.11 (1.83–2.43) Po0.001
Most deprived quintile 87 (5) 45 (2) 1919 1.93 (1.56–2.39) Po0.001
Other four quintiles 274 (8) 122 (3) 3593 2.25 (1.99–2.54) Po0.001
Abbreviations: CI¼ confidence interval; IMD = index of multiple deprivation; O/E = Observed/Expected; PEARL= Practice Endorsed Additional Reminder Letter.
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Although we have made the assumption that it is the GP
endorsement that has led to our observed increase in uptake, due to
the design of our study we cannot be certain whether an additional
reminder letter from the Hub would in itself increase uptake in the
programme. As summarised by Duffy et al (2016), reminders have
been demonstrated to increase uptake in screening programmes.
However, only two studies have reported the effect of postal reminders
alone on participation, one of pre-appointment breast screening
reminders (Allgood et al, 2016) and one of reminders following non-
attendance in cervical screening (Eaker et al, 2004). Although both
studies found an increase in participation with the reminders, it is not
clear whether these results would generalise to the Bowel Cancer
Screening Programme in the UK. To our knowledge, no studies
assessing the impact of a second reminder letter have been published.
In our primary standardised analysis, the effect of the intervention in
terms of raw numbers was to increase participation by 371 (6914–
6543) when all invitees are considered. Restricting analysis to those
who had not returned an adequate kit by the index date (the target
population of the intervention), the effect was an increase of 195 (362–
167). In the matched analysis, the figures would be 512 (6914–6914/
1.08) (Table 4) and 196 (362–362/2.18), respectively. One could
therefore be confident that the effect of adopting these reminders as
policy would lie within the range of these figures. In terms of the larger
number of participants estimated to accrue when all invitees are
considered, it is not out of the question that the intervention had some
effect on participation among those not sent a PEARL reminder but
living with a subject who did receive a reminder.
During the intervention period, 3149 GP-endorsed reminders
were sent in the PEARL-registered practices. The resulting absolute
increase in participation was of the order of 200 in the target
population. This is consistent with the observation that of those
adequately screened, but not before the index date, in the PEARL-
registered practices, 250 actually received a reminder. For each
extra participant, between 6 and 16 PEARL reminders had to be
sent, depending on which estimate one considers. The PEARL-
registered practices were characterised by low socioeconomic status
(Table 1), therefore the intervention has potential to improve
delivery to traditionally underserved populations.
A limitation of this study is that the intervention was not
randomised. However, we did include in the PEARL practices
those which registered whether or not they supplied lists, to
approximate an intention to treat analysis. Also, the similar results
by two separate approaches, taking account of differences between
the PEARL practices and the comparison practices, give some
confidence in the results.
Two practices that had agreed to take part in the PEARL project
did not return any non-responder patient lists but the practices
may still have used the information to target patients—it is not
possible to quantify that effect. The exclusion of non-responders by
GPs could not be replicated in the control population, but this
limitation would be likely to diminish the observed effect of the
intervention. The process is dependent on engagement and active
participation of GP practices and our experience demonstrated that
logistical factors such as use of a generic e-mail address, key staff
members leaving can impact the success of such projects.
The Hub process to generate the GP-endorsed second reminder
letter was robust and became incorporated into the routine workload
of the Southern Hub. For the majority of subjects, the fact the letter
was signed by the subject’s own GP practice and appeared on the
GP’s letterhead (as opposed to a letter signed by an unknown Hub
Director) is likely to have had a positive effect on the subject’s
attitude. Other research has demonstrated that uptake of screening
can be improved by direct contact in person with a GP or other
health professional (Senore et al, 2010), especially in ethnically
diverse populations (Shankleman et al, 2014; Massat et al, 2014),
although such an approach has important resource implications in
terms of cost and time and is probably unsustainable.
The results of this project require qualification, not least the
labour-intensive method and high level of quality control required.
Despite offering a financial incentive, in addition to the potential
benefit to their patients, only 58% of invited GP practices agreed to
participate. Anecdotal reasons given by practices for not
participating in the PEARL project included the amount of time
that would have to be invested, an unusually high turnover of
practice managers, and organisational disruption caused by
practice mergers during the study period.
The reasons given above for non-participation should be
interpreted with caution, The practices invited to take part were
those with the lowest uptake (o55% for prevalent invitations) and
the link between deprivation and low uptake of bowel cancer
screening has been firmly established. It may be that the observations
should not be extrapolated to all GP surgeries on a national scale.
A key consideration for the study was the GP–patient relation-
ship if a letter was coming on GP letter headed paper. This was the
reason the GP was asked to review a list of their patients who had
not responded and who were on the list to receive a reminder. It is
notable that a reasonable number (5.11%) of subjects were deemed
unsuitable to receive the letter from the GP suggesting that sending
out GP-personalised letters without having a GP review in advance
might be inappropriate.
As part of the ASCEND randomised controlled trial in England
(a national trial designed to reduce the social gradient in uptake),
investigators sought permission from general practices to allow the
practice name to be added to the standard BCSP pre-invitation
letter (Wardle et al, 2015; Raine et al, 2016). In all, 80% of practices
agreed. An increase in uptake of 0.7 percentage points was reported
(58.2% vs 57.5%). The authors concluded that, given the
willingness shown by GPs to endorse the BCSP, the small one-
off cost incurred to modify the standard invitation letter and the
overall increase in uptake, the BCSP should consider adding the
GP endorsement to the screening invitation letter. The London
BCSP Hub have implemented the GP endorsement.
Compared with the ASCEND GP-endorsed pre-invitation
intervention (Raine et al, 2016), the PEARL project has demon-
strated a greater impact on uptake, possibly because subjects
received a second reminder that appeared to have been sent by
their own GP. Consideration does need to be given to the feasibility
of PEARL compared with ASCEND. The ASCEND approach
requires only that a GP practice agrees once a year for the
endorsement to be added to the standard letters. In contrast,
PEARL required continuous engagement from GP practices and
created additional work for the Hub. The benefits of the PEARL
approach are clear by the increase in uptake, whether this is
sustainable across the country is questionable when considering
the pressures that GPs face.
We have developed a robust and sustainable method to send GP-
endorsed letters to non-responders. A GP-endorsed second reminder
letter significantly increased uptake, by about 3 percentage points,
both as a proportion of all invitees or only those who had not
returned a test kit by the index date. The extra work required for the
Hub and GPs to support the PEARL intervention should be
evaluated and recommendations made on the feasibility of rolling out
this process nationally within BCSP. The process would require
refinement before being rolled out on a larger scale.
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